临床药物遗传学实施联盟 CYP2D6 基因分型和托莫西汀治疗指南
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
机构信息
Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota College of Pharmacy, Duluth, Minnesota, USA.
Department of Experimental and Clinical Pharmacology, College of Pharmacy, Department of Psychiatry, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
出版信息
Clin Pharmacol Ther. 2019 Jul;106(1):94-102. doi: 10.1002/cpt.1409. Epub 2019 Apr 13.
Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).
阿托西汀是一种非兴奋剂药物，用于治疗注意力缺陷/多动障碍（ADHD）。细胞色素 P450（CYP）2D6 多态性影响阿托西汀的代谢，从而影响药物的疗效和安全性。我们总结了已发表文献中的证据，支持这些关联，并根据 CYP2D6 基因型（www.cpicpgx.org 上的更新）为阿托西汀提供治疗建议。
Zotero 插件